Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William McCall

Psychiatry Augusta, GA Medical Doctor

NPI 1902881485 CMS profile 702550

997 St. Sebastian Way, Georgia Regents Medical Associates, Augusta, GA 30901

Open in the dashboard

General payments

$62,785

102 records reported · program years 2019–2025

Research payments

$10,073

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,310 paid to institutions, not to them · program year 2019

Through program year 2025, William McCall of Augusta, GA is reported in the CMS Open Payments database as having received $62,785 across 102 general payments and $10,073 in research payments paid to them. Separately, studies naming them as principal investigator received $9,310 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,731 7
2024 General $7,760 18
2023 General $26,672 23
2023 Research $10,073 2
2022 General $2,912 17
2021 General $3,615 2
2020 General $1,640 1
2019 General $16,456 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William McCall
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to William McCall were reported at $3,731. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year William McCall Psychiatry median Middle half National median
2019 $16,456 $184 $59–$605 $163
2020 $1,640 $119 $36–$372 $114
2021 $3,615 $143 $43–$576 $132
2022 $2,912 $153 $50–$590 $149
2023 $26,672 $170 $56–$651 $160
2024 $7,760 $179 $57–$673 $164
2025 $3,731 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Idorsia Pharmaceuticals US Inc $29,957 39 payments
  2. Janssen Pharmaceuticals, Inc $11,136 20 payments
  3. LivaNova USA, Inc. $6,276 7 payments
  4. Jazz Pharmaceuticals Inc. $5,321 14 payments
  5. Genentech, Inc. $4,230 2 payments
  6. Eisai Inc. $3,636 2 payments
  7. Sunovion Pharmaceuticals Inc. $1,640 1 payment
  8. Harmony Biosciences LLC $253 3 payments
  9. ITI, Inc. $122 7 payments
  10. Sage Therapeutics, Inc. $50 1 payment
  11. Other $165 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $41,634 20 payments
  2. Travel and Lodging $9,175 24 payments
  3. Honoraria $5,200 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,340 2 payments
  5. Food and Beverage $2,095 50 payments
  6. Education $341 5 payments
Products named General payments · program years 2019–2025
  1. QUVIVIQ $28,397 33 payments
  2. SPRAVATO $11,136 20 payments
  3. VNS THERAPY SYMMETRY MODEL 8103 GENERATOR $6,276 7 payments
  4. XYREM $5,321 14 payments
  5. Dayvigo $3,600 1 payment
  6. LATUDA $1,640 1 payment
  7. Wakix $253 3 payments
  8. CAPLYTA $122 7 payments
  9. REXULTI $50 1 payment
  10. LYBALVI $42 2 payments
  11. Other $241 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Idorsia Pharmaceuticals US Inc $10,073 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

19

Median for Psychiatry: 574

Drug cost

$34

Median for Psychiatry: $27,624

Branded share of claims

0%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lorazepam Generic 19 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$1,120

Medicare's payments for the services billed

Medicare patients

16

Average age 66

Services billed

21

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
Heart failure 0%
COPD 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $1,573
$1,573 — —
CAPLYTA
  • ITI, Inc. $22
$22 — —
ARISTADA
  • Alkermes, Inc. $17
$17 — —
LYBALVI
  • Alkermes, Inc. $4
$4 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record